Lv12
50 积分 2023-03-29 加入
Antibody-drug conjugates as targeted therapies: Are we there yet? A critical review of the current clinical landscape
3小时前
已完结
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
1天前
已完结
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
1天前
已完结
Dosing algorithm revisit for busulfan following IV infusion
3天前
已完结
Criteria to Reevaluate Anti-drug Antibody Assay Cut Point Suitability in the Target Population
16天前
已完结
Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points
16天前
已完结
Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody
1个月前
已完结
Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma
1个月前
已完结
Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method
1个月前
已完结
Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods
1个月前
已完结
皖公网安备34019202002308
